April 2025 eCommunication

Introducing Our 2025-2026 Sponsors

We’re proud to introduce the Canadian Lymphedema Framework’s 2025/26 Sponsors—dedicated partners who share our mission to improve education, awareness, and care for the 1.25 million+ Canadians affected by lymphedema. Their support plays a vital role in advancing research, strengthening advocacy, and delivering meaningful resources to patients, healthcare professionals, and communities across Canada. We’re grateful for their commitment and excited to collaborate in the year ahead.

We hope you will spend some time visiting the websites of these committed companies to explore the products and services they offer. Follow the links, below.

Advancements in Care for Breast Cancer Related Surgery

- Reconstruction and Lymphedema

Join the Canadian Breast Cancer Network for an engaging and educational webinar on the latest advancements in surgical care related to breast cancer, with a focus on breast reconstruction and lymphedema prevention and management.

The Canadian Lymphedema Framework's Vice-Chair Dr. Siba Haykal will explore how innovative surgical techniques are helping to improve outcomes, support recovery, and enhance the overall quality of life for individuals affected by breast cancer.

If you would like to learn more and to register your attendance, click below:

Visit the CBCN Website to Register

April is Cancer Awareness Month

Cancer and cancer treatments are among the most common causes of secondary lymphedema in North America. Individuals with cancer (e.g. breast, prostate, gynecological, melanoma, lymphoma, and other cancers) have a lifelong risk for developing lymphedema if they have had lymph nodes or vessels removed or damaged during treatment.

To learn more about cancer related lymphedema, visit our Lymphedema Learning Library, below.

Visit the Learning Library Now

April is Head and Neck Cancer Awareness Month

In Canada, an estimated 7,400 Canadians will be diagnosed with head and neck cancer annually. Head and neck lymphedema (HNL) is a significant and commonly neglected side effect, from surgery and/or radiation therapy.

HNL could manifest externally (e.g. skin, face, neck, head), internally (e.g. oral cavity, tongue, pharynx) or both.

Prevalence of HNL ranges between 12% to 90% for external HNL, and as high as 97% for internal HNL.

To learn more about HNL click the link below to access our Lymphedema Resource Library which features a curated collection of Pathways articles.

Visit the Learning Library Now